GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Geron Corp (LTS:0IV3) » Definitions » Float Percentage Of Total Shares Outstanding

Geron (LTS:0IV3) Float Percentage Of Total Shares Outstanding : 95.65% (As of May. 16, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Geron Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Geron's float shares is 609.24 Mil. Geron's total shares outstanding is 636.92 Mil. Geron's float percentage of total shares outstanding is 95.65%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Geron's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Geron's Institutional Ownership is 31.02%.

Geron Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Geron's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=609.24/636.92
=95.65%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Geron Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Geron Corp (LTS:0IV3) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
ELVN PHVS NRIX RCUS ZYME MLYS NTLA SYRE GYRE VIR VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
GERN:USA GON:Germany
Address
919 East Hillsdale Boulevard, Suite 250, Foster City, CA, USA, 94404
Website
https://www.geron.com
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Geron Headlines

No Headlines